scispace - formally typeset
P

P. E. De Jong

Researcher at University Medical Center Groningen

Publications -  70
Citations -  5607

P. E. De Jong is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Renal function & Filtration fraction. The author has an hindex of 35, co-authored 70 publications receiving 5399 citations. Previous affiliations of P. E. De Jong include Tufts University & University of Vienna.

Papers
More filters
Journal ArticleDOI

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

TL;DR: A large number of patients in the pooled analysis would provide sufficient statistical power to detect relationships between patient characteristics and risk for progression of renal disease and interactions of patient characteristics with treatment effect, and strong and consistent results from analysis would clarify the effects of ACE inhibitors for treatment of nondiabetic renal disease.
Journal ArticleDOI

Meta-analysis identifies multiple loci associated with kidney function–related traits in east Asian populations

Yukinori Okada, +414 more
- 01 Aug 2012 - 
TL;DR: A meta-analysis of genome-wide association studies for kidney function–related traits, including 71,149 east Asian individuals from 18 studies in 11 population-, hospital- or family-based cohorts, conducted as part of the Asian Genetic Epidemiology Network (AGEN), identified 17 loci newly associated with kidney function-related traits.
Journal ArticleDOI

Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.

TL;DR: A significantly greater antiproteinuric effect of 'non-ACEI' antihypertensives was found in diabetic patients compared to non-diabetics, and this coincided with a greater blood pressure reduction in diabetics.
Journal ArticleDOI

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis

TL;DR: Treatment with co-trimoxazole reduces the incidence of relapses in patients with Wegener's granulomatosis in remission and is identified as an independent factor associated with prolonged disease-free survival and a positive antineutrophil cytoplasmic antibody test at the start of treatment as a risk factor for relapse.